Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. Additionally we are shipping VHL Antibodies (111) and VHL Proteins (7) and many more products for this protein.
Showing 4 out of 7 products:
Loss of Vhl in mesenchymal progenitors of the limb bud caused severe fibrosis of the synovial joints and formation of aggressive masses with histologic features of mesenchymal tumors.
These data suggested that intestinal epithelial cells were injured after IM treatment through the pVHL overexpression-induced degradation of collagen I or HIF-1alpha (show HIF1A ELISA Kits).
Vhl and Kif3a (show KIF3A ELISA Kits) deletion accelerates renal cyst formation
maintains the stability and suppressive function of Foxp3 (show FOXP3 ELISA Kits)+ T cells via regulation of HIF-1a (show HIF1A ELISA Kits) pathway
Deletion of the Vhl gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.
Molecular dynamics of hif-1alpha (show HIF1A ELISA Kits) and VHL may determine the success of antineoplastic strategies in hypoxia-reoxygenation as predicted by computational modeling.
Loss of Vhl in adult joint cartilage is associated with earlier dysregulation of cartilage homeostasis, characterized by increased chondrocyte apoptosis, compromised chondrocyte autophagy and accelerated age-related and surgery-induced OA development.
Both Vhl and Bap1 (show BAP1 ELISA Kits) are required for kidney function. Even when Vhl is inactivated in multipotent nephron progenitor cells, Vhl loss is insufficient for renal tumorigenesis.
VHL deficiency perturbs pancreas endocrine homeostasis in mice.
data suggest that the VHL-mediated signaling in osteochondral progenitor cells plays a critical role in bone remodeling at postnatal/adult stages through coupling osteogenesis and angiogenesis
HBV induces the HIF2alpha (show EPAS1 ELISA Kits) expression through its encoded protein HBx. This upregulates the HIF-2alpha (show EPAS1 ELISA Kits) expression by binding to the pVHL activating the NF-kappaB (show NFKB1 ELISA Kits) signaling pathway
inhibition of miR566 expression increases the expression levels of VHL, decreases the expression levels of VEGF, and inhibits the invasive and migratory abilities of glioblastoma.
proteome and phospho-proteomic analysis of isogenic 786-O renal cell carcinoma (+/-VHL) cells to compare signatures that reflect hypoxia and/or loss of VHL protein
Pars (show EPRS ELISA Kits) plana vitrectomy in advanced VHL eye disease can improve or preserve visual function, but postoperative progression of ocular VHL disease can be accelerated in cases where retinotomy is performed.
AR-suppressed miRNA-145 is a key player in renal cell carcinoma progression by regulating HIF2alpha (show EPAS1 ELISA Kits)/VEGF (show VEGFA ELISA Kits)/MMP9 (show MMP9 ELISA Kits)/CCND1 (show CCND1 ELISA Kits) expression levels, irrespective of VHL status.
VHL was shown to influence cellular metabolism through its effect on HIF proteins as well as by affecting activity of other factors.
Data indicate that mutant VHL can protect HIF1alpha (show HIF1A ELISA Kits) from SART1 (show SART1 ELISA Kits)-dependent degradation in normoxic conditions, but this protection is lost in hypoxic settings, favoring hypoxia-dependent ccRCC proliferation.
VHLp19 has a role for regulating EPO (show EPO ELISA Kits) levels that VHLp30 does not have, whereas VHLp30 is really the tumor suppressor isoform.
pVHL interacts with CERKL and ubiquitinates it for oxygen dependent proteasomal degradation.
APOE, VHL and MTHFR gene polymorphisms were related to the risk of renal cell carcinoma
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
, von Hippel-Lindau disease tumor suppressor
, von Hippel-Lindau syndrome homolog
, von Hippel-Lindau syndrome protein homolog
, elongin binding protein
, protein G7